Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from HUTCHMED (China) ( (HK:0013) ).
HUTCHMED (China) Limited has announced that as of April 30, 2026, its issued share capital comprises 872,335,120 ordinary shares of US$0.10 each, with each share carrying one voting right and no shares held in treasury. This figure serves as the denominator for shareholders assessing disclosure obligations under the UK Financial Conduct Authority’s transparency rules, and corresponds to the number of depositary interests on AIM or, if fully converted, 174,467,024 American depositary shares on Nasdaq, clarifying the company’s capital and voting structure across its multiple listings.
More about HUTCHMED (China)
HUTCHMED (China) Limited is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. It advances drug candidates from in-house discovery to global markets, with three medicines already marketed in China and its first product also approved in the US, Europe and Japan.
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.